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Mycobacterium malmoense is a potentially pathogenic species that was first described in 1977.
During the past decade M. malmoense has been recognized with increasing frequency as a pulmo-
nary pathogen. More than 180 cases of M. malmoense infection have been reported. Most of
these infections affected a previously damaged lung. Other infection sites included the skin,
lymph nodes, and bursae. Five cases of disseminated infection have been reported. The antituber-
culous drugs associated with the most favorable susceptibility patterns are rifampin and etham-
butol. Because of the slow growth of M. malmoense on conventional, egg-based bacteriologic
media, the incubation time should be >6 weeks; special solid and liquid media are recommended.
We report a case of disseminated pulmonary and gastrointestinal infection due to M. malmoense
in a patient with AIDS, who was treated successfully with a combination of rifabutin (ansamy-
cin), clofazimine, and isoniazid. In addition, we review the characteristics of extrapulmonary and
disseminated infections due to M. malmoense.
Human disease caused by Mycobacterium malmoense is
rare. More than 180 cases of M. malmoense infection have
been reported since this potentially pathogenic nontubercu-
lous species of Mycobacterium was first described by
Schroder and Juhlin in 1977 [1]. Most of these cases con-
sisted of pulmonary disease that, in terms of symptomatol-
ogy and manifestations, resembled pulmonary infection due
to Mycobacterium tuberculosis. Nevertheless, two important
differences were noted in cases of infection due to M. mal-
moense.• (1) a poor correlation between results of in vitro
drug susceptibility tests and clinical response to chemother-
apy [2-4] and (2) a lack of transmission to healthy contacts
(whether such infection can be transmitted to immunocom-
promised persons has not been decided [5-10]. Therefore,
infection-control and contact-tracing procedures need not be
applied in response to M. malmoense infections. In contrast
with extensive reports of pulmonary infections [11-17], case
reports of extrapulmonary and disseminated disease due to
M. malmoense have been sparse.
Parallel to the continuing epidemic of AIDS, an increasing
incidence of diseases caused by either M. tuberculosis or non-
tuberculous mycobacteria (NTM) has been observed [9, 18].
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In persons with advanced AIDS, Mycobacterium aviuni com-
plex (MAC) is the most frequent cause of mycobacterial in-
fection; in addition, disseminated infection due to MAC is
one of the most common opportunistic infections in this pa-
tient population [9, 10, 19]. Nevertheless, other species of
NTM, including Mycobacterium kansasii and Mycobacte-
rium haentophilum, have also been shown to cause dissemi-
nated disease in patients with AIDS [20, 21]. In 1985 Good
reported the first finding of a single isolate of M. malmoense,
which was recovered in the laboratories of the Centers for
Disease Control (CDC; Atlanta) from a pool of mycobacte-
rial isolates from 212 patients with AIDS [22]. In the mean-
time, the recovery of three clinically significant M. mal-
moense strains from specimens from men infected with the
human immunodeficiency virus (HIV) in developing coun-
tries was reported [23].
The first cases of pulmonary and disseminated disease due
to M. malmoense in HIV-infected men were described in
1991 [24]. We report herein another case of disseminated
infection with M. malmoense in a patient with AIDS and
review the characteristics of 21 cases of extrapulmonary and
disseminated disease due to M. malmoense.
Case Report
In October 1990 a 42-year-old homosexual man com-
plained of having had severe night sweats, fever, productive
cough, and severe watery diarrhea for the previous 3 weeks.
In 1986 serology for HIV had been found to be positive. In
February 1989, HIV infection in CDC stage IVA associated
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with impaired cellular immunity (CD4 lymphocyte count,
40/mm 3 ) had been diagnosed after weight loss, intermittent
diarrhea (results of staining of stool specimens for acid-fast
bacilli were negative), and persistent fever with night sweats
were reported. At that time, therapy with zidovudine was
started. In February 1990 the HIV infection had shown signs
of further progression with the development of oral candidia-
sis (CDC stage IVC2).
When we examined the patient in October 1990, he was
thin and almost cachectic. Generalized micropolyadeno-
pathy was noted. Loud, widespread rhonchi, corresponding
to a history of heavy smoking and chronic obstructive lung
disease, were heard during auscultation. There were no aus-
cultatory signs of pneumonia. No hepatosplenomegaly was
found. Results of clinical laboratory tests were not remark-
able except for a slightly elevated level of alkaline phospha-
tase. Routine hematology showed (zidovudine-induced)
macrocytic anemia (hemaglobin concentration, 12 g/dL)
and a normal leukocyte count with normal differentiation.
The sedimentation rate was higher than normal but un-
changed in comparison with that noted in previous tests (78
mm/h). The CD4 lymphocyte count had declined to 10/
mm 3 . A roentgenogram of the chest showed a newly devel-
oped acinar infiltrate in the right upper lobe; no abnormali-
ties had been noted on a roentgenogram obtained 7 months
before. Neither apical scarring nor mediastinal or hilar
lymphadenopathy were evident. Ultrasonography of the ab-
domen revealed slightly enlarged paraaortal and hepatohilar
lymph nodes. Microscopic examination of specimens of spu-
tum (seven times), feces (five times), and bronchoalveolar
lavage fluid (one time) yielded acid-fast bacilli. A tuberculin
skin test with 2 IU (corresponding to 5 U) of PPD-S pro-
duced no reaction. Antituberculous therapy was started with
isoniazid (300 mg/d), pyrazinamide (1,800 mg/d), and ri-
fampin (720 mg/d).
After 4 weeks, mycobacterial culture of stool and sputum
yielded NTM and the therapeutic regimen was modified; ri-
fabutin (ansamycin, Farmitalia Carlo Erba AG, Zug, Swit-
zerland; 600 mg/d), clofazimine (300 mg/d), ethambutol
(1,500 mg/d), and isoniazid (300 mg/d) were administered.
At 7 weeks his condition was unchanged, and the severe
diarrhea, cough, and fever had not abated. Meanwhile, M.
malmoense was identified on the basis of testing with stan-
dard biochemicals and the fatty-acid profile (obtained with
gas-liquid chromatography). The patient was treated with iso-
niazid (300 mg/d), rifabutin (600 mg/d), and clofazimine
(200 mg/d). The administration of ethambutol had to be
discontinued because of gastrointestinal side effects). M.
malmoense was found in five stool specimens and seven spu-
tum samples (all smears were microscopically positive for
acid-fast bacilli). Cultures of blood (4 samples) and urine ( I
sample) for mycobacteria remained negative. With use of the
proportion method and Middlebrook 7H 10 agar plates, it
was determined that the isolated strain was susceptible to
rifampin (M1C, 1.0 mg/L), rifabutin (0.12 mg/L), and clofa-
zimine (1.0 mg/L) and resistant to isoniazid (1.0 mg/L), eth-
ambutol (16 mg/L), streptomycin (2.0 mg/L), amikacin (5.0
mg/L), cycloserine (50 mg/L), ofloxacin (2.0 mg/L), and
ciprofloxacin (2.0 mg/L). (The proportion method demon-
strates susceptibility when, at a given concentration, the
yield of cfu is <1 (7i. of that obtained with a drug-free control.)
The patient continued to suffer from coughing. slight he-
moptysis, and severe watery diarrhea. Bronchoalveolar la-
vage revealed severe chronic bronchitis and microscopically
numerous acid-fast bacilli (later confirmed as M. mal-
moense), but no other cause of the pulmonary disease was
evident. Transbronchial biopsy showed a nonspecific lym-
phocytic inflammation of the lung tissue, in which no acid-
fast bacilli, granulomas, or giant cells were detected. A cul-
ture for mycobacteria of a transbronchial biopsy tissue
specimen was not performed.
During the following 6 months, diarrhea and coughing
gradually dissipated. The infiltrate in the right upper lobe
started to decrease in size. The patient's compliance with
therapy was confirmed several times by detection of isonia-
zid metabolites and, initially, by the characteristic red color
of rifampin in urine. After 10 months of antituberculous
treatment, results of microscopic examination and cultures
of sputum and feces were negative, and the patient's condi-
tion improved. The diarrhea had disappeared completely.
and there was only little coughing; a chest roentgenogram
showed scar formation in the right upper lobe but no more
evidence of an infiltrate. The patient resumed work on a
part-time basis. The clinical symptoms did not recur. Treat-
ment was continued until 1 5 months after the diagnosis, and
all specimens of stool and sputum remained negative for
acid-fast bacilli.
Literature Review and Discussion
In reviewing the English-language literature for all previ-
ously reported cases of extrapulmonary and disseminated in-
fections with M. malmoense, we referred to two sources, In-
dex Medicos and Current Contents, under the subject
headings nontuberculous nircobacteria and M. malmoense. In
addition, we checked the reviewed literature for further refer-
ences to cases of extrapulmonary and disseminated infec-
tions due to M. ma/moo/sc. The search of the literature from
1967 to September 1992 yielded 15 published reports de-
scribing extrapulmonary infection with M. malmoense. Ade-
quate descriptions of treatment and clinical course were not
always available, especially in regard to cases of cervical lym-
phadenitis. Overall, 21 cases of extrapulmonary and dissemi-
nated infection due to M. malmoense were described in 15
reports.
Clinical Manifestations
The characteristics of all 21 cases of extrapulmonary and
disseminated infections due to M. malmoense are listed in
Patient	 Underlying
disease or risk
factor
Site of infection
and
manifestations Clinical features Diagnostic findings Treatment
Outcome and
comments
age (y)/
Case no.	 Reference	 sex
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Table 1. Characteristics of cases of disseminated infection due to M. malmoense.
2
3
4
5
[25] 59/F	 Atypical chronic
granulocytic
leukemia
treated for 12
mo with
busulfan and
thioguanine
[26] 40/M	 Hairy-cell
leukemia
treated with
a-interferon
2b
[27]	 48/F	 Chronic myeloid
leukemia
(Philadelphia
chromosome
positive)
	
Present	 42/M	 AIDS (CD4
report lymphocyte
count, 40/
mm 3)
Cigarette
smoking
Disseminated:
pulmonary
and cutaneous
manifestations
Disseminated
(most probable
because of
poor general
condition);
enlarged
lymph nodes
of the upper
mediastinum
and infiltration
of the lung
Disseminated,
initially,
supraclavicular
lymph node:
6 mo later,
multiple
tender
indurations,
skin nodules
on the
forearm, back,
buttocks, and
thighs
Disseminated
(most
probable)
Anterior upper
lobe (typical
for NTM)
Chronic cough, multiple
subcutaneous
abscesses
Protracted fever
(temperatures to
40°C)
Night sweats, anorexia,
lethargy, weight loss,
fever, (temperatures to
38°C), no
lymphadenopathy or
splenomegaly
Weight loss, night
sweats, anorexia
Persistent cough,
tachypnea
Jaundice, bowel
disturbance.
peripheral
neuropathy, hepatic
encephalopathy
Poor general
constitution,
intermittent fever,
night sweats, weight
loss
Coughing, hemoptysis
Fine nodular opacities on
chest radiographs,
positive cultures of
subcutaneous abscess
specimens
Widening of the upper
mediastinum;
mediastinoscopy with
lymph node biopsy:
granulomatous
infiltrates with
Langhans' giant cells;
microscopy: acid-fast
bacilli; culture: positive
for M. mahnoense
Lymph node biopsy
numerous acid-fast
bacilli (no culture)
Liver biopsy:
nonnecrotizing
granulomata (no
culture)
Biopsy of cutaneous
lesions: giant and
epithelioid cells, no
acid-fast bacilli; culture:
positive for M.
mahnoense
Sputum: acid-fast bacilli;
culture: positive for M.
mahnoense
Stool: acid-fast bacilli,
culture: positive for M.
malmoense
Abdominal
ultrasonography: dilated
gall bladder (no gall
stones)
ERCP: common bile duct
displaced and narrowed
Smears of feces and
sputum repeatedly
positive; culture:
positive for M.
mahnoense
Bronchoalveolar lavage:
evidence of severe
chronic bronchitis,
numerous acid-fast
bacilli
Rifampin,	 Early death
isoniazid,
ethambutol
Rifampin,	 Remainined
doxycycline,	 afebrile,
ethambutol,	 gained
cycloserine	 weight;
(16 months),	 general
then isoniazid	 condition
only	 still
improving
Rifampin,	 Healing of the
isoniazid:
	
skin lesions
pyrazinamide	 noted in
subsequently	 several weeks
added	 and liver
Streptomycin	 function
added (no	 normal
improvement)	 within 2
months with
Final regimen:	 cycloserine
cycloserine,	 and
ethambutol	 ethambutol
(dramatic	 therapy;
improvement)	 treatment
stopped after
9 mo; no
relapse in
52-y follow-
up
Hepatorenal
failure, then
death
Rifampin,
isoniazid,
pyrazinamide
initially (no
improvement);
ethambutol
subsequently
added (after
9 mo sputum
cultures
became
negative, but
4 mo later
deterioration
was noted)
Rifabutin,	 After 6 mo,
clofazimine,	 coughing and
isoniazid
	
diarrhea
disappeared;
after 8 mo,
patient
resumed
work (part
time); no
relapse
[24]	 56/M	 AIDS (CD4	 Disseminated
lymphocyte	 (most
count, 30/	 probable)
mm3 )	 Base and
Cigarette	 midzone of
smoking	 the right lung
Gastroinestinal
Alcohol abuse	 tract
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Table 1. (Continued)
Patient
	
Underlying	 Site of infection
age (y)/	 disease or risk	 and
	 Outcome and
Case no.	 Reference	 sex	 factor	 manifestations
	 Clinical features	 Diagnostic findings	 Treatment	 comments
Gastrointestinal
tract
Diarrhea tenesmus Transbronchial biopsy:
nonspecific,
lymphocytic
inflammation of lung
tissue, no giant cells,
no acid-fast bacilli (no
culture); no other
pathogens
NOTE. ERCP = endoscopic retrograde cholangiopancreatography.
tables 1, 2, and 3. Three patterns can be distinguished among
the clinical manifestations.
Disseminated infections (table I). Five cases of dissemi-
nated infection due to M. malmoense have been described
(present report included) [24-27]. In all five cases, there was
an underlying cause of immunodeficiency: chronic granulo-
cytic leukemia, hairy-cell leukemia, and chronic myelocytic
leukemia in one case each and AIDS in two cases. In the two
cases in which AIDS was the underlying disease, the periph-
eral blood CD4 lymphocyte count was <100/mm 3 . A defini-
tive diagnosis was made after cultures of specimens from
a subcutaneous abscess (cases 1 and 3), from mediastinal
lymph node biopsy (case 2), and of stool and sputum (cases 4
and 5) were positive for M. malmoense. In cases 3, 4, and 5, a
final diagnosis of disseminated disease could not be made on
the basis of results of cultures of blood, bone marrow, and
liver punction specimens; nevertheless, on the basis of the
general constitution of the patients, such a diagnosis appears
likely. The cases involving AIDS fulfill the criteria for a diag-
nosis of disseminated disease due to NTM in cases of HIV
infection, according to the guidelines of the American Tho-
racic Society (ATS) [10]. The outcomes of the five cases of
disseminated disease included death in two cases (in case 1,
antituberculous treatment was given only for a short time,
but the patient had a progressive underlying disease; in case
4, hepatorenal failure developed after the patient's condition
had improved for after a short time because of antitubercu-
lous therapy). In the other three cases, the patients were
cured by antituberculous treatment according to the results
of in vitro susceptibility tests performed after 16 months
(case 2), 9 months (case 3), and 8 months (case 4) of treat-
ment, respectively.
Tenosynovitis (table 2). Another disease pattern is repre-
sented by three cases of local M. malmoense infection in bur-
sae, one in a hand [28] and two in a forearm [29, 30]. Two of
these cases were associated with risk factors. In case 6 (hand
abscess), the patient had insulin-dependent diabetes and had
received a cortisone injection at the site of the abscess after
swelling of the hand was misinterpreted as a ganglion. In
case 8 (tenosynovitis of forearm flexors with carpal tunnel
syndrome), the patient was an active gardener whose illness
probably was the result of reactivation of M. malmoense in-
fection that had occurred years previously after traumatic
injury of the hand with a rose thorn (for which local steroid
treatment was administered). In case 7 (tenosynovitis of fore-
arm flexors with carpal tunnel syndrome), the patient re-
called no traumatic incident in which inoculation of M. mal-
moense might have occurred.
Cervical lymphadenitis (table 3). Unilateral cervical lym-
phadenitis presenting as abscess is the most frequent extra-
pulmonary infection due to M. malmoense [2, 8, 13, 16, 31],
although other lymph regions can also be affected (e.g., me-
diastinal or submandibular lymph nodes) [11, 32]. Constitu-
tional symptoms are generally absent. In contrast with pul-
monary disease, which occurs predominantly in adults, all
diagnosed cases of lymphadenitis, except one involving a 75-
year-old woman with swelling in the submandibular region,
have been in children [ 1 I ].
Historical Aspects
In 1967 Birn et al. published a study of M. avium and
related NTM in which they described five strains that dif-
fered from M. avium in terms of lipid pattern, serotype, eth-
ionamide resistance, and temperature range for growth [34].
These strains were susceptible to both cycloserine and eth-
ionamide and were either negative or weakly positive for ar-
ylsulphatase. The justification for defining a new species (at
that time named "provisional new species two") was the dis-
tinctive pattern of its surface lipids observed on chromatogra-
phy. Four of the five strains were considered to be definitely
clinically significant. All were the cause of pulmonary dis-
ease in persons who had pneumoconiosis as an underlying
disease. In 1969 Schaefer et al. gave further clinical details
and reported that two patients with infection due to the my-
cobacteria died [33]. Ten years later, in 1976, Schroder sent
seven strains of mycobacteria from Germany to the Mycobac-
terium Reference Unit in Wales, which identified them as
identical to organisms of the "provisional new species two".
In 1977 SchrOder and Juhlin described the new species in a
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Table 2.
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Characteristics of cases of tenosynovitis due to M. mahnoense.
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Case no. Reference
Patient
age (y)/
sex
Underlying disease
or risk factor Site of infection Clinical features Diagnostic findings Treatment
Outcome and
comments
6 [28] 52/M Insulin-dependent
diabetes and
cortisone
injection because
of painful
swelling
Left hand May 1985:
swelling of the
left hand
Feb 1986: tender
scar, sinus
discharging
clear fluid
Ganglion
Serous fluid and
xanthochromatic
granules
Oct 1985: cortisone
injection
Surgery (sinus excision)
Not determined
May 1986:
swelling
Radiography and
bone scanning:
returned
(painful)
no evidence of
osteomyelitis
May 1988:
swelling
tender, firm,
not fluctuating
Pigmented
villonodular
synovitis;
biopsy:
Rifampin, isoniazid,
pyrazinamide
epithelioid
granulomata
(caseating),
many acid-fast
bacilli; culture:
positive for M.
malnwense
7 [29] 73/M No specific history
of trauma
Vaginae
synoviales of
Disturbance of
median nerve
Carpal tunnel
syndrome
Initially, surgical
decompression (not
After 12 mo,
antituberculous
(infection spread forearm sensation successful, synovitis) therapy
hematogenously?) flexors Granulomatous
tenosynovitis
with Langhans'
giant cells, no
acid-fast bacilli;
culture: positive
for M.
malmoense
Surgical intervention,
no antituberculous
therapy (not
successful)
Surgical intervention
(because of relapse 5
mo after second
surgery), this time
with antituberculous
therapy (rifampin,
ethambutol)
discontinued;
patient
remained
asymptomatic
for 2
subsequent
years
8 [30] 6I/F Asthma: 5 mg Synovium of the Loss of sensation Carpal tunnel Surgical decompression Condition
prednisolone
daily for the last
10 y:
corticosteroid
forearm flexor
tendons
in the median
nerve
Wasting of
thenar muscles
syndrome
Histologic
examination:
and isoniazid,
rifampin,
ethambutol,
pyrazinamide (but
improved,
swelling
resolved,
median nerve
injection in the
right carpal
Fluctuant
swelling of the
nonspecific,
chronic synovitis
relapse occurred) sensation
regained:
tunnel because of
signs of nerve
compression:
injury to right
thumb from a
velar forearm Acid-fast bacilli in
initial smear of
specimen from
second
synovectomy:
Second extensive
tenosynovectomy;
antituberculous
therapy (?)
wasting of
thenar muscles
still noted
rose thorn years
previously
culture: positive
for M.
malmoense
report on taxonomic studies, in which they proposed the
name M. malmoense because organisms of the new species
had been first isolated from patients in the Swedish town of
MalmO [1]. Jenkins and Tsukamura reported that from 1954
to 1979 61 isolates of M. malmoense had been recovered
from 11 patients [2]. A retrospective review of these records
showed that M. malmoense was first isolated in 1954, at
which time it was not yet identified as a separate strain [11].
In addition, it may well be possible that before 1954, in cases
in which results of histologic or microscopic examination
were positive but cultures were negative for mycobacteria,
some of the isolates recovered were M. malmoense. In 1979
the first two extrapulmonary infections (cervical lymphaden-
itis in two patients in England) were described [2].
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Microbiology
On the basis of colonial morphology, M. malmoense could
be misidentified as the Mycobacterium terrae complex or
MAC. M. malmoense is distinguished from M. shitnoidei by
only one feature, acid phosphatase activity, of which the de-
tection is among the few tests that are commonly used to
identify mycobacteria. It seems that M. malmoense isolates
do not grow optimally on LOwenstein-Jensen culture me-
dium slants. Therefore, incubation time for primary isolation
should be prolonged to 8-12 weeks [35]. However, growth is
enhanced by the use of acidic egg-based media [36, 37], me-
dia supplemented with either pyruvate [38] or isoniazid [39],
or radiometric broth 12B [40]. Results of this study showed
that broth culture with the Bactec system (Johnston Labora-
tories, Towson, MD) was significantly more sensitive and
rapid for the detection of M. malmoense in tissue samples
than was culture on solid, egg-based medium. M. malmoense
hydrolizes Tween 80, has no acid phosphatase activity,
shows microaerophilic growth [1], and does not grow at
45°C. Because M. malmoense is a rare etiologic agent for
extrapulmonary mycobacteriosis, we recommend that clini-
cally significant isolates should be identified and that their
identification be confirmed at laboratories with experienced
personnel. The chromatography techniques used in these lab-
oratories produce results faster than do traditional biochemis-
try tests.
Epidemiology
Little is known about the epidemiology of M. malmoense.
The possibility that the higher number of isolates of this new
species is the result of greater experience in its identification
can be denied today, since a review of the records in the
Mycobacterium Reference Unit in Wales since 1954 revealed
only a few strains for which the mycobacteriological identifi-
cation was wrong [11]. Thus, improvement in laboratory
techniques per se cannot be the cause of this increase. Today
there is no doubt of a genuine increase of infections due to
M. malmoense, including those infecting sites such as the skin
and bursae. Nevertheless, on the basis of figures from 1987,
Ellis found that M. malmoense has a relatively high affinity
for the respiratory tract in comparison with other NTM [41].
The ratio of respiratory to nonrespiratory cases of infection
due to M. malmoense was —6, whereas for infections due to
other pathogens it was as follows: M. tuberculosis, 2.7; M.
kansasii, 18; MAC, 2.4; and Mycobacterium xenopi, 25.
The most common extrapulmonary infection due to M.
malmoense is cervical adenitis, which has been found to oc-
cur almost exclusively in children. Katila et al. showed that
in 12 cases of bacteriologically verified cervical adenitis in
Finland between 1977 and 1986, MAC was identified in
nine, M. malmoense in two, and M. tuberculosis in only one
[31]. In addition, they drew the interesting conclusion that
neonatal BCG vaccination seems to protect children against
nontuberculous mycobacterial infections. This conclusion
was based on the fact that the incidence of nontuberculous
mycobacterial adenitis became 30 times greater in Sweden
than in Finland after neonatal BCG vaccination had been
stopped. Whether their theory holds true in regard to protec-
tion against infection due to M. malmoense has not been
established.
Disseminated infections have only been described as oc-
curring in association with an underlying immunodeficiency
such as leukemia or AIDS.
Clinical Significance of Isolates
In contrast with other NTM, M. malmoense has been iso-
lated only from human sources and from captured wild ar-
madillos (Dasvpus noyetncinctus) in Louisiana [42]—never
from an inanimate source. Colonization of the gastrointesti-
nal tract in healthy persons has been reported previously by
Portaels et al. [43], but the ramifications of this finding in
terms of epidemicity have not been determined. They found
M. malmoense in the stool of one patient and Mycobacterium
simiae along with M. malmoense in the stool of another.
Whether mycobacteria found in the gastrointestinal tract are
occasional colonizers or a part of the permanent flora has not
been determined.
The presence of characteristic clinical signs and the isola-
tion of M. malmoense from a biopsy specimen that demon-
strates histopathological signs of granulomas normally are
indicative of disease, i.e., in bursae or lymph nodes. How-
ever, most specimens are of sputum; thus, although recovery
of an isolate may indicate disease, it may also indicate tran-
sient contamination of the oropharynx or benign coloniza-
tion of the lung (i.e., in association with chronic bronchitis),
especially if mycobacteria cannot be repeatedly cultured
[44-46].
The present case fulfills the criteria recommended by the
ATS for diagnosis of pulmonary disease caused by NTM
[10], although lung tissue samples did not show any acid-fast
bacilli because of sampling error. The transbronchial biopsy
specimen was not cultured for acid-fast bacilli. It seems that
bronchoalveolar lavage results in a higher diagnostic yield
than does transbronchial biopsy; this has already been shown
for M. tuberculosis [47]. The absence of typical histologic
signs of mycobacterial disease such as granulomas or giant
cells is relatively common in cases of AIDS [48]. Granuloma
formation in HIV-infected patients depends on their state of
immune reactivity.
Positive stool cultures are also difficult to interpret be-
cause asymptomatic patients with stool cultures positive for
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Table 3.
Zaugg et al.
Characteristics of cases of lymphadenitis due to M. malmoense.
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Case no. Reference
Patient age
(y)/sex
Underlying
disease or risk
factor Site of infection Clinical features
Diagnostic
findings Treatment Outcome
9 [33] 9 mo/M None Cervical lymph
node
Small scald Cold abscess;
direct smear:
acid-fast
bacilli; culture:
positive for
Surgery (radical
curettage);
riampin,
isoniazid (6
mo)
Neck fully healed
Al. malmoense
[ 8 1 Mean, 5.2 y None, except in Cervical nodes Swelling (mean Acid-fast bacilli Incision and
range,
1.8-9.7
y/I2 F
and 7M
one case (47%):
submandibular
nodes (32%);
preauricular
nodes (21%);
unilateral, 84%
duration, 6.6 w) in
63%, minimal
tenderness and
fluctuation
(suggestive of cold
abscess); glands:
in 61%;
cultures
positive at 7.9
w; sensitivity
results
obtained in
drainage (61%)
1.5-7 cm; no
systemic upset:
chest radiography
clear for 88%
11.5 w (no
specific data
given)
10 [8] (Child) Prominent right hilus No caseating
granulomas
Partial excision;
incision and
drainage
Uncomplicated (no
sinus)
11 [8] (Child) Caseating
granulomas
Needle aspiration Sinus for 7 mo;
indurated wound
after repeated
surgery
12 [8] (Child) Giant-cell
granulomas
Partial excision Indurated wound
13 [8] (Child) Incision and
drainage
Uncomplicated
14 [8] (Child) Traumatic Mild cough Caseating Incision and Sinus for 4 mo:
lesion granulomas biopsy indurated scar
15 [2] 3 y/F None Cervical lymph
node
Swelling
lymphadenitis
Culture: positive
for M.
malmoense
Alive and well
16 [2] 5 y/F None Cervical lymph
node
Swelling,
lymphadenitis
Culture: positive
for M.
malmoense
Alive and well
17 [13] 9 mo None Cervical lymph
node
Swelling Direct smear:
acid-fast
bacilli; culture:
positive for
Incision and
drainage,
antituberculous
therapy
Sinus formation
M. malmoense (isoniazid,
pyrazinamide,
rifampin)
Second surgical
intervention,
continuous
antituberculous
two-drug
regimen
Alive and well
18 [31] 3y None Cervical lymph
node
Cervical
lymphadenitis
No acid-fast
bacilli; culture:
positive for
M. malmoense
19 [31] 8 y None Cervical lymph
node
Cervical
lymphadenitis
No acid-fast
bacilli; culture:
positive for
M. malmoense
20 [II] 75 y/F None Submandibular
lymph node
Swelling Culture: positive
for M.
malmoense
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Table 3. (Continued)
Underlying
Patient age	 disease or risk
	
Diagnostic
Case no.	 Reference	 (y)/sex	 factor	 Site of infection	 Clinical features	 findings	 Treatment	 Outcome
21	 [32]	 2 y/F	 None	 Intrathoracic
lymph nodes
History of wheezing
and increasing
exertional dyspnea
unresponsive to
salbutamol and
oral coricosteroids,
widespread rhonchi
Chest radiograph:
superior
mediastinal
mass:
computed
tomography:
paratracheal
mass:
histologic
examination of
lymph node:
acid-fast
bacilli. caseous
necrosis:
culture:
positive for M.
malmoense
Extrapleural
approach
(lymph nodes):
no
antituberculous
therapy
Patient remained
asymptomatic
for the next 6 mo
NOTE. Blank spaces denote that data were not given.
M. malmoense have been reported [43]. In addition, the or-
ganism is not an obligate pathogen in the gastrointestinal
tract. This is probably not the case for persons with severe
immunodeficiency, however. For these patients the ATS has
formulated separate criteria for the clinical significance of
evidence of infection due to NTM [9]. The positivity of one
smear prepared from feces or several stool cultures for a cer-
tain species of NTM is sufficient for the diagnosis of dissemi-
nated disease due to NTM in patients with immunodefi-
ciency if other organ systems are involved and clinical signs
of disease are present. Endoscopic biopsy of the gastrointesti-
nal tract as a means of detecting mycobacteria and granulo-
mas is rarely necessary and has only a limited diagnostic
yield [49]. For HIV-seropositive patients with pulmonary in-
fection due to M. tuberculosis, about 40% of the smears pre-
pared from stool specimens are positive, but these patients
do not have any clinical features of gastrointestinal M. tuber-
culosis infection [50-52]. Therefore, in this special situation
the positive smears for acid-fast bacilli are not indicative of
extrapulmonary infection due to M. tuberculosis (swallowed
sputum containing mycobacteria) [53]. These findings do
not pertain to gastrointestinal infections caused by NTM in
HIV-infected patients. As we learned from experience with
MAC infections, disseminated infection appears to be mostly
of gastrointestinal origin. The presence of acid-fast bacilli in
smears of stool specimens and/or the positivity of stool cul-
tures for NTM are results of simple, noninvasive tests that
correlate well with invasive disease if constitutional symp-
toms are present. Clinical signs of gastrointestinal disease in
association with several positive smears and cultures and the
exclusion of other pathogens are therefore sufficient evi-
dence of invasive gastrointestinal disease due to NTM in pa-
tients with AIDS.
Susceptibility and Therapy
The results of susceptibility testing of M. malmoense are
variable. This is probably due to the fact that the methodol-
ogy is only standardized for tubercle bacilli and not for
NTM. M. malmoense is normally susceptible to rifampin and
resistant to isoniazid. Of the 21 cases of extrapulmonary in-
fection due to M. malmoense, susceptibility results were avail-
able in only seven cases. Six strains were susceptible to eth-
ambutol; five, to rifampin. Resistance to isoniazid was noted
in all cases, and to each pyrazinamide and streptomycin, in
two cases. In 1985 Banks et al. published a large review of
treatment for patients with pulmonary disease due to M. mal-
moense [3]: he found poor correlation between results of in
vitro susceptibility tests and clinical success. The best results
with the lowest rate of relapses were achieved with the three-
drug regimen of rifampin/ethambutol/isoniazid adminis-
tered for 18-24 months. Omission of ethambutol was asso-
ciated with an unfavorable course. Other regimens were also
used with second-line drugs, including ethionamide and cy-
closerine, but the responses were poor. Four of ten nonre-
sponders to antituberculous treatment underwent successful
resectional surgery (most successful in cases of radiographi-
cally evident unilateral disease).
Lymphadenitis due to mycobacteria is a relatively com-
mon disease that was described in Shakespeare's Macbeth as
scrofula or King's Evil. In contrast to incidence rates among
adults, nontuberculous lymphadenitis due to NTM is more
common than tuberculous lymphadenitis among children
(except in developing countries); usually M. avium can be
isolated [54-56]. The therapy of choice for nontuberculous
lymphadenitis in general and for cervical lymphadenitis due
to M. malmoense (the most frequent site of such infection) in
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particular is total excision [55-59]. Treatment by means of
incision with drainage, needle aspiration only, or partial ex-
cision should be avoided because of the high rate of asso-
ciated complications such as sinus formation and scarring
(see table 3). Medical treatment is usually not indicated.
Infection of a hand or forearm by NTM is uncommon
[35]. In contrary to the treatment of infections of lymph
nodes, the therapy necessary for local infections caused by
traumatic injury in bursae is debridement and administration
of a combination of antimycobacterial agents; otherwise, re-
lapse is inevitable. In the case of isolation of M. malmoense,
such a combination should include rifampin and etham-
butol.
A review of cases of disseminated disease due to M. mal-
moense does not allow definite recommendations concerning
the best therapeutic regimen. A combination including ri-
fampin, isoniazid, and ethambutol was frequently used. In
two cases of disseminated disease with leukemia as the un-
derlying disease, the second-line drug cycloserine in combi-
nation with ethambutol was successful; the patients were
cured. In our case there was a high resistance to both cyclo-
serine and ethambutol, and we decided to treat with the al-
ternative drugs rifabutin and clofazimine in combination
with isoniazid. Omission of ethambutol did not impair the
clinical success of treatment.
Conclusion
In general, extrapulmonary infection due to M. malmoense
is a rare event. The most frequent infection site is the cervical
lymph node. Disseminated infection has been reported to
occur only in patients with severe immunodeficiency. The
optimal therapy for infections due to M. malmoense is not
well established. This is true not only for pulmonary mani-
festations but particularly for disseminated forms of infec-
tion because of their rare occurrence and association with
different underlying diseases. The drugs associated with the
most favorable susceptibility patterns are rifampin and eth-
ambutol. An increasing number of M. malmoense isolates
from sputum and from extrapulmonary sites of infection
might be observed in the future in countries in which the
prevalence of HIV and M. malmoense infections is high.
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